A. Haloperidol decanoate B. Fluphenazine decanoate C. Paliperidone palmitate D. Aripiprazole monohydrate

A. Risperidone long-acting injection B. Olanzapine pamoate C. Fluphenazine decanoate D. Paliperidone palmitate

A. Haloperidol decanoate B. Risperidone long-acting injection C. Olanzapine pamoate D. Aripiprazole monohydrate

A. Family support B. Medication adherence C. Medication dosage D. Age at time of first psychotic event

A. Patients who have requested to receive a LAIA B. Patients who are veterans C. Patients who are homeless D. Patients with frequent hospitalizations and criminal activity

A. Less than 10% B. About 30% C. About 50% D. About 80%

A. Almost no patients B. About one-third of patients C. About two-thirds of patients D. Almost every patient

A. Patient has adequate adherence to oral medication B. Patient refuses to use an injectable medication C. LAIA are not dependable for prevention of relapse D. LAIA have too many adverse effects

A. Patients are most afraid of loss of autonomy and injection site pain B. Patients are most afraid of the stigmatizing nature of injections C. Patients are most afraid of being forced to use LAIA by prescribers D. Patients are fearful that the LAIA will not be as effective as oral medication

A. Significantly more adherent than those who were not in ACT B. Slightly more adherent than those who were not in ACT C. Equally adherent as those who were not in ACT D. Less adherent than those who were not in ACT